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Abstract
This review addresses the apparent disconnect between international guideline recommendations,
real-life clinical practice and the results of clinical trials, with regard to the initiation of insulin using
basal (long-acting) or premixed insulin analogues in patients with type 2 diabetes (T2D). English
language guidelines varyconsiderably with respect to recommended glycaemic targets, the selection of
human vs analogue insulin, and choice of insulin regimen. Randomised trials directly comparing
insulin initiation between basal and premixed analogues are scarce, and hard endpoint outcome data
are inadequate. The evidence presented suggests that a major component of the HbA1c not being
attained in every day clinical practice may be a result of factors that are not adequately addressed in
forced titration trials of highly motivated patients, including failure to comply with complex treatment
and monitoring regimens. Enforced intensiﬁcation of unrealistic complex treatment regimens and
glycaemic targets may theoretically worsen the psychological well-being in some patients. More simple
and sustainable treatment regimens and guidelines are urgently needed. As for the use of insulin in
T2D, there is limited evidence to convincingly support that initiation of insulin using basal insulin
analogues is superior to initiation using premixed insulin analogues. While awaiting improved clinical
efﬁcacy and cost-effectiveness data, practical guidance from national and international diabetes
organisations should consider more carefully the importance of: i) being clear and consistent; and
ii) the early implementation of sustainable and cost-effective insulin treatment regimens with an
emphasis on optimising treatment ease of use and patient compliance.
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Introduction
The treatment of diabetes mellitus is becoming increas-
ingly complex as physicians are required to select
between a growing number of oral and injectable
therapies. In addition to weighing up the advantages
and disadvantages of each of these drug classes, there
can also be substantial differences in efﬁcacy and safety
of treatments within the same drug class (1). We are
also beginning to identify patients who seeminglydo not
respond to treatment, remaining in poor glycaemic
control, experiencing a high frequency of drug-related
side effects (such as severe hypoglycaemia and weight
gain), and/or developing earlier micro- and macro-
vascular complications (2). Indeed, this distinct
segment of the type 2 diabetes (T2D) population,
characterised by severe resistance to the current
available pharmacological as well as non-pharma-
cological glucose-lowering treatment regimens, may
account for the adverse outcomes in the Action to
Control Cardiovascular Risk in Diabetes (ACCORD)
study (2, 3). Similarly, the aforementioned group of
‘severely therapy-resistant’ patients with T2D may
account for the U-shaped relationship between HbA1c
and mortality observed in the UK General Practice
Research Database (GPRD) (4). It should be noted that
such U- or J-shaped curves between HbA1c and
mortality have also been observed in individuals
without diabetes, i.e. at levels of HbA1c considered
normal and therefore uninﬂuenced by glucose-lowering
medication (5). These results could suggest a need for
more individualised treatments and goal setting,
acknowledging that some therapy-resistant patients
with long-lasting T2D should not necessarily aim for
HbA1c values below 7.5% using currently available
treatment modalities (6).
While the adverse cardiovascular risk associated with
the diagnosis of T2D has been reported in many
epidemiological studies (7, 8, 9, 10), there is increasing
concern over the cost-effectiveness of currently used
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for instance, antihypertensive and lipid-lowering thera-
pies in T2D (11). Meanwhile, the prevalence of T2D
continues to rise, substantially increasing the burden
of T2D on already overstretched healthcare systems.
Regardless of healthcare infrastructure and
differences in recommended HbA1c levels, many
surveys indicate that too many patients, and in
particular those patients requiring insulin treatment,
remain above even the most conservative recommen-
dations for glycaemic targets(12, 13). Insulin treatment
is usually commenced late in the course of the disease,
and in some patients, after many years of high
glycaemic burden. A recent epidemiological study
found the population median HbA1c to be between
7.8 and 8.1%, but that HbA1c values were as high as 9
and 10% before treatment intensiﬁcation to com-
bination oral antidiabetic drugs (OADs) or the initiation
of insulin respectively (4). Documented perceived
patient and physician barriers to the use of insulin
include the risk of hypoglycaemia and weight gain (14).
Injection frequency and complexity continues to be
among the most important considerations for patients
receiving insulin treatment (15).
The most convenient and simple ways to initiate
insulin treatment in patients with T2D are most
probably the use of long-acting basal insulin at bedtime
or injection of premixed insulin before one or more
meals. While most studies support the notion that
currently available analogue formulations of both basal
and premixed insulin are superior to their human
insulin counterparts with respect to the risk of
hypoglycaemia (16, 17), there is a lack of a uniform
consensus as to which of the two regimens should be
recommended to initiate insulin treatment in patients
with T2D. This review critically investigates the
apparent disconnect between international guideline
recommendations, real-life clinical practice and the
results of clinical trials with regard to the use of basal
(once-daily) and premixed (once- or twice-daily) insulin
analogues. The evidence presented suggests that a
major component of the HbA1c not being attained in
routine clinical practice may be the result of factors
that are not addressed in forced titration clinical trials,
such as the complexity of current treatment regimens
and insulin titration, both of which may have a negative
impact on treatment adherence.
Methodology
Relevant publications were identiﬁed by means of a
PubMed literature search in the period January 1990
to June 2010. Other studies were identiﬁed from the
bibliography of short-listed articles. The search criteria
used the Medical Subject Headings (MeSH): ‘basal
insulin, premixed insulin, premix insulin, insulin,
T2D, guidelines’; and ‘randomised controlled trial
phase 1, phase 2, phase 3 or phase 4’ clinical trial.
The search was limited to English language publi-
cations. Supplementary references for guidelines were
identiﬁed via Google. An initial review of all titles and
abstracts was performed for relevance. If deemed
appropriate for further review, access to the full article
was obtained. Randomised controlled studies were
included if at least one of the reported trial arms
comprised treatment with either a basal or a premixed
insulin analogue in any combination with OADs.
Clinical trials
Presently, the two most common approaches to
initiating insulin treatment are with abasal or premixed
insulin regimen. Although manyguidelines recommend
premixed insulin to be initiated with twice-daily
injections, it is well documented that some patients
can achieve glycaemic targets with one injection daily
only (18, 19, 20). The choice of regimen has historically
been a reﬂection of regional practice and physician
preference, as well as patient-speciﬁc considerations
including assessment of the fasting and postprandial
blood glucose and lifestyle factors. Interestingly,
however, very few studies directlycompare the initiation
of basal and premixed insulin analogue regimens in
randomised clinical trial designs (21, 22, 23, 24, 25,
26, 27, 28, 29, 30) (Table 1).
A recent systematic reviewand meta-analysis of basal
and premixed regimens included four of the aforemen-
tioned studies in a pooled analysis of HbA1c and weight,
demonstrating that the twice-daily premixed insulin
regimens reduced HbA1c by an additional 0.45% (CI
0.19–0.70%), but with an additional weight gain of
1.3 kg which did not reach statistical signiﬁcance (CI
K0.4 to 3 kg) (21, 28, 29, 30, 31). Hypoglycaemia
could not be analysed due to the variation in deﬁnitions
and lack of measures of dispersion. Two studies
published after the analysis comparing once- and
twice-daily premixed regimens with a once-daily basal
insulin analogue also demonstrated signiﬁcantly lower
end of trial HbA1c with the premixed regimens (23, 24).
The study by Kann et al. (25), probably excluded from
the meta-analysis on the basis of unbalanced OAD
treatment between treatment arms, may nevertheless
represent a valid treatment comparison and also
demonstrated a 0.5% additional reduction in HbA1c
with a twice-daily premixed regimen in combination
with metformin compared with a once-daily basal
insulin and sulphonylurea.
In the studies directly comparing premix with basal
insulin analogue regimens shown in Table 1, weight
gain associated with both regimens appears to reﬂect
the overall improvement in glycaemic control. The
additional weight gain with the premixed regimens
ranged between 0 and C2.8 kg relative to the basal
regimens, with the largest weight difference recorded
160 A Vaag and S Lund EUROPEAN JOURNAL OF ENDOCRINOLOGY (2012) 166
www.eje-online.orgT
a
b
l
e
1
R
a
n
d
o
m
i
s
e
d
c
o
n
t
r
o
l
l
e
d
t
r
i
a
l
s
c
o
m
p
a
r
i
n
g
b
a
s
a
l
a
n
d
p
r
e
m
i
x
e
d
i
n
s
u
l
i
n
a
n
a
l
o
g
u
e
r
e
g
i
m
e
n
s
i
n
p
r
e
v
i
o
u
s
l
y
i
n
s
u
l
i
n
-
n
a
ı
¨
v
e
p
a
t
i
e
n
t
s
w
i
t
h
t
y
p
e
2
d
i
a
b
e
t
e
s
:
b
a
s
e
l
i
n
e
d
e
m
o
g
r
a
p
h
i
c
a
n
d
t
r
e
a
t
m
e
n
t
e
f
f
e
c
t
s
.
A
g
e
(
m
e
a
n
G
S
.
D
.
)
;
d
u
r
a
t
i
o
n
o
f
d
i
a
b
e
t
e
s
(
m
e
a
n
G
S
.
D
.
)
o
r
(
m
e
d
i
a
n
(
q
u
a
r
t
i
l
e
s
)
)
.
T
r
i
a
l
I
n
s
u
l
i
n
t
r
e
a
t
m
e
n
t
O
A
D
t
r
e
a
t
m
e
n
t
S
t
u
d
y
H
b
A
1
c
(
%
)
H
y
p
o
g
l
y
c
a
e
m
i
a
W
e
i
g
h
t
R
e
f
.
C
l
a
s
s
P
r
e
p
a
r
a
t
i
o
n
O
A
D
C
h
a
n
g
e
f
r
o
m
b
a
s
e
l
i
n
e
D
u
r
a
t
i
o
n
(
w
e
e
k
s
)
P
a
t
i
e
n
t
s
(
n
)
M
a
l
e
(
%
)
D
i
a
b
e
t
e
s
d
u
r
a
t
i
o
n
(
y
e
a
r
s
)
B
a
s
e
l
i
n
e
E
O
T
E
p
i
s
o
d
e
s
D
e
ﬁ
n
i
t
i
o
n
C
h
a
n
g
e
(
k
g
)
(
2
4
)
P
r
e
m
i
x
e
d
L
M
2
5
c
P
r
e
v
i
o
u
s
/
2
4
f
1
0
4
5
5
3
9
.
7
G
6
.
3
9
.
1
G
1
.
3
7
.
2
G
1
.
1
2
8
.
0
h
S
/
B
G
!
7
0
m
g
/
d
l
C
3
.
6
G
4
.
0
B
a
s
a
l
I
g
l
a
r
d
1
0
4
6
5
3
9
.
3
G
5
.
9
9
.
0
G
1
.
2
7
.
3
G
1
.
1
2
3
.
1
h
C
2
.
5
G
4
.
0
(
2
1
)
P
r
e
m
i
x
e
d
N
M
3
0
c
P
r
e
v
i
o
u
s
/
5
2
f
2
3
5
6
8
9
.
0
(
6
.
0
,
1
2
.
0
)
8
.
6
G
0
.
8
7
.
3
G
0
.
9
5
.
7
h
B
G
!
5
6
m
g
/
d
l
C
4
.
7
G
4
.
0
B
a
s
a
l
I
d
e
t
d
2
3
4
6
1
9
.
0
(
6
.
0
,
1
2
.
0
)
8
.
4
G
0
.
8
7
.
6
G
1
.
0
2
.
3
h
C
1
.
9
G
4
.
2
(
2
6
)
P
r
e
m
i
x
e
d
L
M
5
0
!
2
C
L
M
2
5
e
P
r
e
v
i
o
u
s
/
1
6
g
6
0
5
7
8
.
4
G
4
.
9
9
.
2
G
1
.
3
7
.
1
G
0
.
1
1
0
.
8
b
,
h
B
G
!
5
4
m
g
/
d
l
C
2
.
0
G
0
.
4
B
a
s
a
l
I
g
l
a
r
d
7
.
3
G
0
.
1
1
.
2
b
,
h
C
1
.
5
G
0
.
5
(
2
5
)
P
r
e
m
i
x
e
d
N
M
3
0
c
C
M
e
t
Y
2
8
f
1
2
8
5
4
1
0
.
3
G
7
.
5
9
.
2
G
1
.
4
7
.
5
G
1
.
1
2
0
.
3
i
B
G
!
5
6
m
g
/
d
l
C
0
.
7
B
a
s
a
l
I
g
l
a
r
d
C
S
U
Y
1
2
7
4
9
1
0
.
2
G
6
.
2
8
.
9
G
1
.
3
7
.
9
G
1
.
3
9
.
0
i
C
1
.
5
(
2
8
)
P
r
e
m
i
x
e
d
L
M
5
0
e
P
r
e
v
i
o
u
s
Y
2
4
f
5
4
5
9
5
.
9
G
3
.
0
8
.
1
G
1
.
2
6
.
5
(
7
.
1
,
6
.
4
)
a
5
.
5
b
,
h
S
/
B
G
!
5
4
m
g
/
d
l
C
1
.
8
G
3
.
4
B
a
s
a
l
I
g
l
a
r
d
5
3
4
3
5
.
5
G
2
.
8
8
.
1
G
1
.
3
7
.
3
(
7
.
8
,
6
.
7
)
a
3
.
7
b
,
h
C
0
.
7
G
3
.
8
(
2
9
)
P
r
e
m
i
x
e
d
L
M
2
5
c
C
M
e
t
Y
1
6
g
1
0
5
6
3
b
9
.
0
G
6
.
6
b
8
.
7
G
1
.
3
7
.
4
G
1
.
1
8
.
4
b
,
h
S
/
B
G
!
6
3
m
g
/
d
l
C
2
.
3
G
1
.
0
B
a
s
a
l
I
g
l
a
r
d
7
.
8
G
1
.
1
4
.
8
b
,
h
C
1
.
6
G
1
.
0
(
3
0
)
P
r
e
m
i
x
e
d
N
M
3
0
c
C
M
e
t
G
T
Z
D
Y
2
8
f
1
1
7
5
3
9
.
5
G
5
.
9
9
.
7
G
1
.
5
6
.
9
G
1
.
2
3
.
4
h
S
/
B
G
!
5
6
m
g
/
d
l
C
5
.
4
G
4
.
8
B
a
s
a
l
I
g
l
a
r
d
1
1
6
5
6
8
.
9
G
4
.
8
9
.
8
G
1
.
4
7
.
4
G
1
.
2
0
.
7
h
C
3
.
5
G
4
.
5
(
2
3
)
P
r
e
m
i
x
e
d
N
M
3
0
d
C
M
e
t
C
S
U
?
2
6
f
2
3
1
4
7
9
.
1
G
5
.
8
8
.
5
G
1
.
0
7
.
1
6
.
5
S
/
B
G
!
5
6
m
g
/
d
l
C
1
.
7
B
a
s
a
l
I
g
l
a
r
d
2
3
8
4
1
9
.
5
G
6
.
1
8
.
5
G
1
.
1
7
.
3
4
.
8
C
1
.
7
R
e
f
.
,
r
e
f
e
r
e
n
c
e
s
;
E
O
T
,
E
n
d
o
f
t
r
e
a
t
m
e
n
t
;
L
M
2
5
,
l
i
s
p
r
o
m
i
x
2
5
;
L
M
5
0
,
l
i
s
p
r
o
m
i
x
5
0
;
I
g
l
a
r
,
i
n
s
u
l
i
n
g
l
a
r
g
i
n
e
;
N
M
3
0
,
N
o
v
o
M
i
x
3
0
;
I
d
e
t
,
i
n
s
u
l
i
n
d
e
t
e
m
i
r
;
M
e
t
,
m
e
t
f
o
r
m
i
n
;
S
U
,
s
u
l
p
h
o
n
y
l
u
r
e
a
;
T
Z
D
,
t
h
i
a
z
o
l
e
d
i
n
e
d
i
o
n
e
;
/
,
u
n
c
h
a
n
g
e
d
;
Y
,
r
e
d
u
c
e
d
;
?
,
u
n
k
n
o
w
n
;
B
G
,
b
l
o
o
d
g
l
u
c
o
s
e
;
S
/
B
G
,
S
y
m
p
t
o
m
s
o
r
B
G
.
a
V
a
l
u
e
s
o
b
t
a
i
n
e
d
b
y
d
i
g
i
t
i
s
i
n
g
p
u
b
l
i
s
h
e
d
ﬁ
g
u
r
e
s
.
b
V
a
l
u
e
s
o
b
t
a
i
n
e
d
b
y
c
a
l
c
u
l
a
t
i
o
n
s
b
a
s
e
d
o
n
p
u
b
l
i
s
h
e
d
d
a
t
a
.
c
B
I
D
t
w
i
c
e
d
a
i
l
y
.
d
Q
D
o
n
c
e
d
a
i
l
y
.
e
T
I
D
t
h
r
i
c
e
d
a
i
l
y
.
f
P
a
r
a
l
l
e
l
s
t
u
d
y
d
e
s
i
g
n
.
g
C
r
o
s
s
o
v
e
r
s
t
u
d
y
d
e
s
i
g
n
.
h
I
n
c
i
d
e
n
c
e
r
e
p
o
r
t
e
d
a
s
e
v
e
n
t
s
p
e
r
p
a
t
i
e
n
t
y
e
a
r
.
i
P
r
e
v
a
l
e
n
c
e
r
e
p
o
r
t
e
d
a
s
%
w
i
t
h
a
t
l
e
a
s
t
o
n
e
e
v
e
n
t
.
Insulin initiation 161 EUROPEAN JOURNAL OF ENDOCRINOLOGY (2012) 166
www.eje-online.orgT
a
b
l
e
2
A
l
l
r
a
n
d
o
m
i
s
e
d
c
o
n
t
r
o
l
l
e
d
t
r
i
a
l
s
c
o
m
p
r
i
s
i
n
g
a
b
a
s
a
l
i
n
s
u
l
i
n
a
n
a
l
o
g
u
e
r
e
g
i
m
e
n
i
n
p
r
e
v
i
o
u
s
l
y
i
n
s
u
l
i
n
-
n
a
ı
¨
v
e
p
a
t
i
e
n
t
s
w
i
t
h
t
y
p
e
2
d
i
a
b
e
t
e
s
.
B
a
s
a
l
a
n
a
l
o
g
u
e
a
r
m
b
a
s
e
l
i
n
e
d
e
m
o
g
r
a
p
h
i
c
a
n
d
t
r
e
a
t
m
e
n
t
e
f
f
e
c
t
s
,
l
i
s
t
e
d
i
n
r
a
n
k
o
r
d
e
r
a
c
c
o
r
d
i
n
g
t
o
d
u
r
a
t
i
o
n
o
f
d
i
a
b
e
t
e
s
.
A
g
e
(
m
e
a
n
G
S
.
D
.
)
o
r
(
m
e
d
i
a
n
(
q
u
a
r
t
i
l
e
s
)
)
;
d
u
r
a
t
i
o
n
o
f
d
i
a
b
e
t
e
s
(
m
e
a
n
G
S
.
D
.
)
o
r
(
m
e
d
i
a
n
(
q
u
a
r
t
i
l
e
s
)
)
.
T
r
i
a
l
I
n
s
u
l
i
n
t
r
e
a
t
m
e
n
t
O
A
D
t
r
e
a
t
m
e
n
t
S
t
u
d
y
H
b
A
1
c
(
%
)
H
y
p
o
g
l
y
c
a
e
m
i
a
W
e
i
g
h
t
R
e
f
.
P
r
e
p
.
R
e
g
i
m
e
n
O
A
D
C
h
a
n
g
e
f
r
o
m
b
a
s
e
l
i
n
e
D
u
r
a
t
i
o
n
(
w
e
e
k
s
)
P
a
t
i
e
n
t
s
(
n
)
M
a
l
e
(
%
)
D
i
a
b
e
t
e
s
d
u
r
a
t
i
o
n
(
y
e
a
r
s
)
B
a
s
e
l
i
n
e
E
O
T
E
p
i
s
o
d
e
s
D
e
ﬁ
n
i
t
i
o
n
C
h
a
n
g
e
(
k
g
)
(
2
8
)
I
g
l
a
r
Q
D
Y
2
4
c
5
3
4
3
5
.
5
G
2
.
8
8
.
1
G
1
.
3
7
.
3
(
7
.
8
,
6
.
7
)
a
3
.
7
b
,
e
S
/
B
G
!
5
4
m
g
/
d
l
C
0
.
7
G
3
.
8
(
4
2
)
I
g
l
a
r
Q
D
/
4
8
c
1
2
1
4
8
6
.
5
G
4
.
9
9
.
4
G
1
.
2
6
.
9
5
.
0
e
B
G
!
7
0
m
g
/
d
l
C
3
.
9
(
3
4
)
I
g
l
a
r
Q
D
C
M
e
t
/
S
U
/
1
6
c
1
3
8
4
7
7
.
4
G
8
.
2
b
9
.
0
G
1
.
2
b
7
.
6
2
.
6
e
S
/
B
G
!
6
0
m
g
/
d
l
C
3
.
3
G
4
.
7
b
(
3
6
)
I
d
e
t
Q
D
F
B
G
!
5
.
0
/
2
0
c
1
2
2
5
6
7
.
9
8
.
0
6
.
8
7
.
5
e
S
/
B
G
!
5
6
m
g
/
d
l
C
0
.
9
G
0
.
4
(
3
8
)
I
g
l
a
r
Q
D
K
S
U
C
M
e
t
Y
3
6
c
5
5
5
3
8
.
2
G
5
.
3
8
.
7
G
0
.
7
7
.
1
G
0
.
8
a
,
b
6
.
0
e
S
/
B
G
!
7
2
m
g
/
d
l
C
2
.
8
G
3
.
5
(
3
9
)
I
g
l
a
r
Q
D
p
m
C
S
U
Y
2
8
c
2
2
7
5
8
8
.
2
9
.
1
G
1
.
0
8
.
1
G
1
.
3
4
3
.
0
f
S
/
B
G
!
7
5
m
g
/
d
l
C
3
.
7
G
3
.
6
(
8
6
)
I
g
l
a
r
Q
D
U
s
u
a
l
/
l
a
b
/
2
4
c
1
4
9
1
5
2
8
.
4
G
6
.
4
8
.
9
G
1
.
5
7
.
5
3
.
7
e
B
G
!
7
0
m
g
/
d
l
N
o
t
g
i
v
e
n
(
8
6
)
I
g
l
a
r
Q
D
U
s
u
a
l
/
P
O
C
/
2
4
c
1
3
6
3
5
3
8
.
4
G
6
.
4
8
.
9
G
1
.
6
7
.
3
3
.
7
e
B
G
!
7
0
m
g
/
d
l
N
o
t
g
i
v
e
n
(
8
7
)
I
g
l
a
r
Q
D
G
M
e
t
G
S
U
G
T
Z
D
/
2
6
1
1
6
6
6
8
.
4
G
6
.
4
8
.
5
G
0
.
7
7
.
3
G
1
.
1
b
3
6
.
8
f
B
G
!
6
0
m
g
/
d
l
C
3
.
0
G
3
.
2
b
(
2
6
)
I
g
l
a
r
Q
D
/
1
6
d
6
0
5
7
8
.
4
G
4
.
9
9
.
2
G
1
.
3
7
.
3
G
0
.
1
2
.
4
b
,
e
B
G
!
5
4
m
g
/
d
l
C
1
.
5
G
0
.
5
(
4
4
)
I
g
l
a
r
Q
D
/
2
4
c
3
6
7
5
5
8
.
4
G
5
.
6
8
.
6
G
0
.
9
7
.
0
9
.
2
e
B
G
!
5
6
m
g
/
d
l
N
o
t
g
i
v
e
n
(
8
6
)
I
g
l
a
r
Q
D
A
c
t
i
v
e
/
l
a
b
/
2
4
c
1
5
0
1
4
9
8
.
6
G
6
.
4
8
.
9
G
1
.
6
7
.
5
6
.
0
e
B
G
!
7
0
m
g
/
d
l
N
o
t
g
i
v
e
n
(
8
6
)
I
g
l
a
r
Q
D
A
c
t
i
v
e
/
P
O
C
/
2
4
c
1
3
6
6
5
0
8
.
7
G
6
.
4
8
.
8
G
1
.
5
7
.
3
6
.
0
e
B
G
!
7
0
m
g
/
d
l
N
o
t
g
i
v
e
n
(
3
0
)
I
g
l
a
r
Q
D
C
M
e
t
G
T
Z
D
Y
2
8
c
1
1
6
5
6
8
.
9
G
4
.
8
9
.
8
G
1
.
4
7
.
4
G
1
.
2
0
.
7
e
S
/
B
G
!
5
6
m
g
/
d
l
C
3
.
5
G
4
.
5
(
2
1
)
I
d
e
t
Q
D
/
5
2
c
2
3
4
6
1
9
.
0
(
6
.
0
,
1
2
.
0
)
8
.
4
G
0
.
8
7
.
6
G
1
.
0
2
.
3
e
B
G
!
5
6
m
g
/
d
l
C
1
.
9
G
4
.
2
(
3
6
)
I
d
e
t
Q
D
F
B
G
!
6
.
1
/
2
0
c
1
2
2
6
4
9
.
0
7
.
9
7
.
0
5
.
3
e
S
/
B
G
!
5
6
m
g
/
d
l
C
0
.
1
G
0
.
4
(
8
8
)
I
g
l
a
r
Q
D
/
4
4
2
0
4
5
2
9
.
0
G
6
.
8
8
.
7
G
1
.
0
7
.
0
G
0
.
7
4
.
2
e
B
G
!
6
0
m
g
/
d
l
C
3
.
0
G
4
.
3
(
2
9
)
I
g
l
a
r
Q
D
C
M
e
t
Y
1
6
d
1
0
5
6
3
b
9
.
0
G
6
.
6
b
8
.
7
G
1
.
3
7
.
8
G
1
.
1
4
.
8
b
,
e
S
/
B
G
!
6
3
m
g
/
d
l
C
1
.
6
G
1
.
0
(
3
9
)
I
g
l
a
r
Q
D
a
m
C
S
U
Y
2
8
c
2
3
6
5
2
9
.
0
9
.
1
G
1
.
0
7
.
8
G
1
.
2
5
6
.
0
f
S
/
B
G
!
7
5
m
g
/
d
l
C
3
.
9
G
4
.
5
(
4
7
)
I
g
l
a
r
Q
D
C
M
e
t
Y
3
6
6
1
6
2
9
.
0
G
7
.
8
b
9
.
5
G
0
.
8
b
7
.
1
G
0
.
8
b
5
.
4
e
B
G
!
7
2
m
g
/
d
l
C
3
.
5
G
5
.
5
b
(
4
5
)
I
d
e
t
Q
D
/
B
I
D
/
5
2
c
2
9
1
5
7
9
.
1
G
6
.
1
8
.
6
G
0
.
8
7
.
2
G
1
.
7
b
2
.
9
e
B
G
!
5
6
m
g
/
d
l
C
3
.
0
G
6
.
8
b
(
4
5
)
I
g
l
a
r
Q
D
/
5
2
c
2
9
1
5
9
9
.
1
G
6
.
4
8
.
6
G
0
.
8
7
.
1
G
1
.
7
b
2
.
9
e
B
G
!
5
6
m
g
/
d
l
C
3
.
9
G
6
.
8
b
(
8
9
)
I
g
l
a
r
Q
D
/
2
6
2
6
0
5
7
9
.
2
G
5
.
7
8
.
3
G
1
.
0
7
.
1
G
1
.
6
a
,
b
6
.
3
e
S
/
B
G
!
6
0
m
g
/
d
l
C
1
.
8
G
3
.
0
a
,
b
(
2
4
)
I
g
l
a
r
Q
D
/
2
4
c
1
0
4
6
5
3
9
.
3
G
5
.
9
9
.
0
G
1
.
2
7
.
3
G
1
.
1
2
3
.
1
e
S
/
B
G
!
7
0
m
g
/
d
l
C
2
.
5
G
4
.
0
(
4
6
)
I
g
l
a
r
Q
D
a
m
C
S
U
Y
2
4
c
3
1
2
5
5
9
.
5
G
6
.
1
8
.
8
G
1
.
0
7
.
2
G
1
.
1
4
3
.
1
f
S
/
B
G
!
5
0
m
g
/
d
l
C
2
.
1
(
2
3
)
I
g
l
a
r
Q
D
C
M
e
t
C
S
U
?
2
6
c
2
3
8
4
1
9
.
5
G
6
.
1
8
.
5
G
1
.
1
7
.
3
4
.
8
e
S
/
B
G
!
5
6
m
g
/
d
l
C
1
.
7
(
4
1
)
I
d
e
t
B
I
D
/
2
4
c
2
2
7
4
9
9
.
6
G
6
.
6
8
.
6
G
0
.
8
6
.
8
3
.
7
e
B
G
!
5
4
m
g
/
d
l
C
1
.
2
(
2
7
)
I
g
l
a
r
Q
D
C
S
U
G
M
e
t
/
2
4
1
7
7
6
1
9
.
9
G
7
.
3
8
.
8
G
1
.
0
7
.
2
G
0
.
9
4
.
1
e
B
G
!
6
0
m
g
/
d
l
C
1
.
4
G
3
.
4
(
3
5
)
I
g
l
a
r
Q
D
/
4
9
c
1
0
3
5
5
1
0
.
0
G
6
.
2
7
.
6
G
0
.
3
6
.
8
G
0
.
7
5
5
.
3
f
S
y
m
p
t
o
m
s
C
0
.
9
G
2
.
9
(
2
5
)
I
g
l
a
r
Q
D
C
S
U
Y
2
8
c
1
2
7
4
9
1
0
.
2
G
6
.
2
8
.
9
G
1
.
3
7
.
9
G
1
.
3
9
.
0
f
B
G
!
5
6
m
g
/
d
l
C
1
.
5
(
3
7
)
I
g
l
a
r
Q
D
C
S
U
Y
2
4
c
2
3
1
4
3
1
0
.
3
G
6
.
4
9
.
1
G
1
.
0
7
.
7
G
1
.
3
5
.
0
e
S
y
m
p
t
o
m
s
N
o
t
g
i
v
e
n
(
4
6
)
I
g
l
a
r
Q
D
C
S
U
Y
2
4
c
3
1
2
5
5
1
0
.
3
G
6
.
8
8
.
8
G
1
.
0
7
.
2
G
1
.
1
3
8
.
4
f
S
/
B
G
!
5
0
m
g
/
d
l
C
1
.
8
(
4
3
)
I
d
e
t
Q
D
a
m
/
2
0
c
1
6
5
5
9
1
0
.
5
G
7
.
6
9
.
1
G
1
.
0
7
.
5
G
1
.
0
9
1
/
3
2
g
B
G
!
5
6
m
g
/
d
l
C
1
.
2
(
4
3
)
I
d
e
t
Q
D
p
m
/
2
0
c
1
6
9
5
4
1
0
.
5
G
7
.
0
8
.
9
G
1
.
0
7
.
4
G
0
.
8
8
2
/
2
7
g
B
G
!
5
6
m
g
/
d
l
C
0
.
7
R
e
f
.
,
r
e
f
e
r
e
n
c
e
s
;
P
r
e
p
.
,
P
r
e
p
a
r
a
t
i
o
n
;
I
g
l
a
r
,
i
n
s
u
l
i
n
g
l
a
r
g
i
n
e
;
I
d
e
t
,
i
n
s
u
l
i
n
d
e
t
e
m
i
r
;
Q
D
,
o
n
c
e
d
a
i
l
y
;
B
I
D
,
t
w
i
c
e
d
a
i
l
y
;
M
e
t
,
m
e
t
f
o
r
m
i
n
;
S
U
,
s
u
l
p
h
o
n
y
l
u
r
e
a
;
T
Z
D
,
t
h
i
a
z
o
l
e
d
i
n
e
d
i
o
n
e
;
/
,
u
n
c
h
a
n
g
e
d
;
Y
,
r
e
d
u
c
e
d
;
?
,
u
n
k
n
o
w
n
;
B
G
,
b
l
o
o
d
g
l
u
c
o
s
e
;
S
/
B
G
,
S
y
m
p
t
o
m
s
o
r
B
G
.
a
V
a
l
u
e
s
o
b
t
a
i
n
e
d
b
y
d
i
g
i
t
i
s
i
n
g
p
u
b
l
i
s
h
e
d
ﬁ
g
u
r
e
s
.
b
V
a
l
u
e
s
o
b
t
a
i
n
e
d
b
y
c
a
l
c
u
l
a
t
i
o
n
s
b
a
s
e
d
o
n
p
u
b
l
i
s
h
e
d
d
a
t
a
.
c
P
a
r
a
l
l
e
l
s
t
u
d
y
d
e
s
i
g
n
.
d
C
r
o
s
s
o
v
e
r
s
t
u
d
y
d
e
s
i
g
n
.
e
I
n
c
i
d
e
n
c
e
r
e
p
o
r
t
e
d
a
s
e
v
e
n
t
s
p
e
r
p
a
t
i
e
n
t
y
e
a
r
.
f
P
r
e
v
a
l
e
n
c
e
r
e
p
o
r
t
e
d
a
s
%
w
i
t
h
a
t
l
e
a
s
t
o
n
e
e
v
e
n
t
.
g
P
r
e
v
a
l
e
n
c
e
r
e
p
o
r
t
e
d
a
s
n
u
m
b
e
r
o
f
e
v
e
n
t
s
/
n
u
m
b
e
r
o
f
p
a
t
i
e
n
t
s
.
162 A Vaag and S Lund EUROPEAN JOURNAL OF ENDOCRINOLOGY (2012) 166
www.eje-online.orgcomparing premix with an insulin detemir regimen.
Whilst it is perhaps unsurprising that the overall
incidence of hypoglycaemia is higher in patients treated
with premixed regimens to lower overall mean HbA1c
values, the rates of nocturnal hypoglycaemia reported
in these studies are not so consistent. Two of these
studies reported a signiﬁcantly lower incidence of
nocturnal hypoglycaemia in patients receiving pre-
mixed regimens (24, 32). However, all studies were
subject to being open label due to the problems and
safety concerns with respect to blinding, and only the
4T study followed patients for over 6 months (21, 22).
In the 4Tstudy, 708 patients with T2D and a median
duration of diabetes of 9 years were randomised to
receive a basal insulin once-daily (insulin detemir),
premixed insulin twice-daily (premixed insulin aspart
30) or a prandial insulin regimen thrice-daily (insulin
aspart). The HbA1c at the end of the ﬁrst year was 7.6,
7.3 and 7.2%, respectively; whilst rates of minor
hypoglycaemia were 2.3, 5.7 and 12.0 events/year
respectively (21). During the subsequent 2-year study
extension, patients not reaching glycaemic targets
progressed to more intensive treatment regimens (22).
Patients initiated on basal insulin were intensiﬁed to a
basal-bolus regimen comprising four injections, and
patientsinitiatedonthepremixedinsulinregimenadded
a single additional prandial injection at lunch. At the
end of the 3 years there was no statistical difference in
the meanHbA1c (7.1% inthe premixedgroupand 6.9%
inthebasalgroup).Basedonloweroverallratesofminor
hypoglycaemia over the 3 years, reduced weight gain,
and perceived convenience, the authors recommended
in favour of once-daily basal insulin as ﬁrst-line insulin
therapy. However, these conclusions ignore the overall
lower rates of treatment intensiﬁcation in the premix
group, that the HbA1c levels and risk of hypoglycaemia
were similar in all three studygroups after the ﬁrst year,
and that the overall between group comparison of
weight did not reach statistical signiﬁcance (33).
Tables 2 and 3 summarise the intention-to-treat
results from other randomised clinical trials in pre-
viouslyinsulin-naı ¨vepatientswithT2Dinwhichatleast
one ofthearmsofthe trialinvestigatestheeffectofeither
a basal or a premixed insulin analogue. For the purpose
of this review, only the basal (Table 2) (18, 21, 23, 24,
26, 27, 28, 29, 30, 34, 35, 36, 37, 38, 39, 40, 41, 42,
43,44,45,46,47)orpremixed(Table3)(18,21,23,24,
25, 26, 28, 29, 30, 48, 49, 50, 51) analoguetrial arm is
included. Basal analogues have been studied in patients
with median 9.0 years’ (quartiles 8.4, 9.5 years)
duration of diabetes. Study’ arms comprising premixed
preparations tended to predominate in patients with a
longer duration of diabetes, median of 9.5 years
(quartiles 8.4, 10.4 years), and if we were to exclude
trialsinwhichpremixedpreparationswereadministered
once-daily only, duration of diabetes increased to a
median 9.9 years (quartiles 9.2, 11.0 years). It is not
surprisingtoﬁndthatthereisconsiderablebetween-trial
variation with respect to duration of diabetes and other
baseline demographics. Sometimes this may reﬂect
general differences between patient populations from
which study participants are recruited, and on other
occasions the study inclusion criteria may differ
according to the research hypothesis. Despite randomis-
ation, however, a few trials also showquite large within-
trial variation, particularly with respect to duration of
diabetes. Although these differences do not reach
statistical signiﬁcance, in at least three instances, a 6–
12 months more progressed cohort received the
hypothesised inferior therapy (37, 39, 44). Whilst this
does not sound like a long time, 4T demonstrated that
20% of patients initiating basal insulin treatment
required bolus insulin intensiﬁcation within the ﬁrst 6
months of the trial (21).
Guidelines
Numerous guidelines on the treatment of diabetes exist.
Some are speciﬁcally deﬁned as national guidelines but
owing to publication on the Internet are only limited by
the reader’s (patients as well as healthcare providers)
ability to understand the language in which it was
written. In the English speaking community, the most
inﬂuential guidelines are probably those published in the
name of the American Diabetes Association (ADA), the
European Association for the Study of Diabetes (EASD)
(52)andtheInternationalDiabetesFederation(IDF)(53);
however, a number of other national guidelines, such as
those published by the American Association of Clinical
Endocrinologists (AACE) (54), the Canadian Diabetes
Association (CDA) (55) and the National Institute of
Clinical Excellence (NICE) (56, 57) are also easily
accessible and well respected (Table 4). The aforemen-
tioned publications vary considerably in size and scope:
with the consensus ADA/EASD and AACE guidelines
issuing practical guidance, and organisations such as
NICE providing highly detailed review and analysis of
the literature followed by broad recommendations.
On the point of initiation of insulin treatment alone,
the guidance varies immensely. The recently published
AACE recommendations state that any one of the four
different approaches to insulin initiation may be
undertaken, including a once-daily basal insulin regi-
men, a premixed insulin preparation which can be
administered once or twice-daily, a basal-bolus regimen
comprising a rapid- and long-acting insulin, or a
prandial regimen (54). The published joint position
statements from the ADA and EASD, however, only
recommend the use of basal insulin in the ﬁrst instance
(58). A number of authors have expressed concern over
the oversimpliﬁcation and lack of physician choice,
failure to address postprandial glycaemic control, and
choice of glycaemic targets, not just in the latest
ADA/EASD consensus guideline but also in that
published in 2006 (59, 60, 61, 62, 63, 64).
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are desirable features of initiation with a once-daily
basal insulin analogue. However, whilst bedtime admin-
istrationof long-actinginsulinappearstoamelioratethe
nocturnal hepatic glucose overproduction, and in some
patients with a shorter duration of disease, causes
sustained blood glucose reductionthroughout the day, it
is the defect in the early insulin response in relation to
meals which is believed to be the primary insulin
secretory defect in the majority of patients with T2D.
Defective ﬁrst-phase insulin response and the resulting
elevations in postprandial glucose is also found in
patients with normal fasting glucose, and is being
increasingly recognised as having a potential indepen-
dent role in diabetes progression (65, 66). To a large
extent, there seems to be agreement on the need
to address prandial glucose control after failure of
basal insulin to achieve HbA1c targets. In this regard,
additionalinjectionsoflong-actinginsulindonotappear
to be effectivein lowering prandial glucose(65)and may
theoretically promote iatrogenic insulin resistance as a
result of constant high levels of plasma insulin (67), and
therefore may not provide any major signiﬁcant clinical
advantage over once-daily basal insulin administration
in many patients (45). In contrast, premixed insulin
preparations exhibit increasing efﬁcacy in reducing
HbA1c when administered more than once-daily (19,
68). Intuitively, it would probably be easier for patients
and physicians to adapt to more frequent injections of
the same insulin preparation compared with adding
rapid-acting insulin to existing basal therapy, or switch-
ing from a once-daily basal to a twice-daily premixed
insulin regimen (20, 69). In addition, the theoretical
concerns regarding the dose adjustment of premixed
(insulin with ﬁxed proportions of rapid- and intermedi-
ate-acting insulin) during intensiﬁcation from once- to
twice-daily and from twice- to thrice-daily mentioned in
the joint ADA/EASD guideline (52), have not been
realised in clinical studies of patients with T2D (68, 70).
The most likelyexplanation for this may be the presence
of insulin resistance and conserved endogenous insulin,
and glucagon secretion in patients with T2D, ensuring
balanced homoeostasis of glucose regulation.
Although all of the aforementioned guidelines
recognise that insulin analogues are associated with a
lower risk of hypoglycaemia, the guidance on their use
as ﬁrst-line insulin treatments remain conﬂicting.
Recommendations with regard to the use of insulin
analogues compared with human insulin preparations
range from ﬁrm recommendations to speciﬁcally avoid
the use of human insulin (54), through unstated
preference (52, 55), to an indicated preference for
human insulin (57). The NICE guidance gives more
weight to the health economic arguments that are
driven primarily by reductions in HbA1c as opposed to
reductions in rates of hypoglycaemia. In this instance,
treatment recommendations are based on the results of
treat-to-target trials, which NICE also acknowledges
give the same glycaemic control due to their inherent
design. With the increasing burden of diabetes for the
patient as well as for society, there is an increasing
focus on cost-effectiveness of diabetes management.
While the focus in the debate is often on the additional
costs of insulin analogues (71), the effect of regimen
complexity and side effects on treatment non-adher-
ence, blood glucose monitoring, patient education and
clinic attendance are also likely to contribute to the
overall expense of diabetes management. Most health
economic analyses do not take these additional cost
considerations into account.
Clinical practice and outcomes
Although the speciﬁc HbA1c target remains conten-
tious, even the most conservative targets are not met by
many patients worldwide. Estimates from European and
US studies have reported that 45 and 37% of patients
have HbA1c values O7.5 and O8.0% respectively (12).
Recently, published registry data for the UK suggests
that very little improvement in glycaemic control
occurred in the period 1997–2007 (72). In this study,
HbA1c improved by only 0.1% from a mean HbA1c of
8.5%. This is in contrast with more successful
reductions in blood pressure (w5%) and total choles-
terol (25%). Similar trends have been reported in the
US, whereby the proportion of patients with HbA1c
O9.0% has remained relatively constant at between 29
and 48% depending on the type of healthcare insurance
cover (73). The ACCORD study demonstrated that even
in a clinical trial, achievement of glycaemic targets
remains difﬁcult with currently available therapies (2).
Despite free and more frequent access to treatment,
25% of the intensively treated cohort of patients still
had HbA1c values over 7.0%. This group of patients
received between three and ﬁve OAD therapies, and
w70% were also receiving insulin. These results
suggest that even under optimal healthcare service
provision, the available therapeutic options are
inadequate in a signiﬁcant proportion of patients.
Insulin initiation currentlyoccurs in w5% of patients
peryearfromdiagnosisorﬁrstOADprescription(74,75,
76, 77), increasing to 10% per year following failure of
combination OAD therapy (78). Although the majority
of patients show some degree of willingness to take
insulin if prescribed (79), this does not necessarily mean
that patients will be able to implement effective self-care
(80, 81). An important element of self-care is the ability
of the patient to comply with treatment recommen-
dations. Regimen complexity is one of the factors
associated with poor compliance. OAD adherence rates
of 79, 66 and 38% have been reported for once-, twice-
and thrice-daily treatment regimens respectively (82).A
substantial proportion of patients also omit insulin
injections, particularly if administration is perceived to
interfere with daily activities (83). These differences in
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factors such as patient psychosocial well-being and
access to healthcare. They also imply a lack of
implementable guidance at a local practice level. With
regard to insulin use, however, training programmes
alone appear to be insufﬁcient. Dale et al. (84) reported
that 3 years after an insulin initiation training
programme, 33% of practices still reported median
HbA1c of over 8.0% in insulin-treated patients. These
results suggest that whilst guidance can have a positive
impact on patient management, practical guidelines on
the optimal use (regardless of choice) of insulin remains
inadequate in terms of scope and/or simplicity.
Conclusions
Ideally, patients should be offered the least intrusive
treatment regimens with the least number of side
effects. Where insulin is concerned, there is a demand
for greater treatment acceptability, treatment compli-
ance and patient satisfaction, a lower risk of hypogly-
caemia and weight gain, as well as sustainabilityof good
glycaemic control eventually leading to improved
outcomes according to hard endpoints including
mortality, micro- and macrovascular disease. In
addition, unlike the majority of clinical trials, insulin
treatment is not limited to 26–52 weeks, and therefore,
insulin initiation should also take into consideration the
lifestyle changes and educational implications of every
subsequent insulin intensiﬁcation step (85). At present,
there seems to be insufﬁcient evidence that insulin
initiation using basal long-acting insulin preparations is
superior to insulin initiation using premixed insulin
analogues, which in contrast to basal insulin prep-
arations may result in sustainable glycaemic control
when used more than once daily. Emerging insulin
therapies should therefore address the issue of regimen
complexity both at initiation and intensiﬁcation and be
more adaptable to patient lifestyle.
Cost-effectiveness analyses must also take into
account the additional expenses required to support
patients on complex treatment regimens, and the effect
these regimens have on patient adherence (14, 83).
Patient quality of life may be most effectively improved
through the elimination of unrealistically complex or
unproven treatment regimens, and unnecessarily strin-
gent glycaemic targets.
In conclusion, there is signiﬁcant room to improve
treatment, including optimal glycaemic control in
patients with T2D. The implementation of future
treatment modalities should also be based on much
more solid clinical evidence than is current practice.
Meanwhile, it is vital that practical consensus guidance
from national and international diabetes organisations
are: i) clear and consistent; ii) take into account the
effects of failing multiple treatment steps on overall
exposure to high glycaemic levels over prolonged
periods; and iii) consider more broadly the implications
of treatment ease of use and dosing regimen on patient
psychosocial factors and compliance.
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